MAGE-A1 (h): 293 Lysate: sc-112260



The Power to Question

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors, and based on their virtually exclusive tumor-specific expression in adult tissues, have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens and are expressed in tumors of different histologic types, but not in normal tissues, with the exception of testis and placenta. Although a large number of MAGE genes have now been identified and extensively studied in tumors of various origin, their function in normal cells remains unknown.

REFERENCES

- Okami, J., Dohno, K., Sakon, M., Iwao, K., Yamada, T., Yamamoto, H., Fujiwara, Y., Nagano, H., Umeshita, K., Matsuura, N., Nakamori, S. and Monden, M. 2000. Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin. Cancer Res. 6: 2326-2332.
- 2. Granelli, P., Siardi, C., Zennaro, F., Cattaneo, M., Malferrari, G., Buffa, R., Fociani, P., Fregoni, F., De Ruberto, F., Fichera, G., Peracchia, A. and Biunno, I. 2000. Melanoma antigen genes 1 and 2 are differentially expressed in human gastric andcardial carcinomas. Scand. J. Gastroenterol. 35: 528-533.
- 3. Klein, C., Bueler, H. and Mulligan, R.C. 2000. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191: 1699-1708.
- Busam, K.J., Iversen, K., Berwick, M., Spagnoli, G.C., Old, L.J. and Jungbluth, A.A. 2000. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod. Pathol. 13: 459-465.
- Kobayashi, Y., Higashi, T., Nouso, K., Nakatsukasa, H., Ishizaki, M., Kaneyoshi, T., Toshikuni, N., Kariyama, K., Nakayama, E. and Tsuji, T. 2000. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 32: 612-617.
- 6. Luiten, R. and van der Bruggen, P. 2000. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens 55: 149-152.
- Osterlund, C., Töhönen, V., Forslund, K.O. and Nordqvist, K. 2000. MAGE-B4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. Cancer Res. 60: 1054-1061.

CHROMOSOMAL LOCATION

Genetic locus: MAGEA1 (human) mapping to Xq28.

PRODUCT

MAGE-A1 (h): 293 Lysate represents a lysate of human MAGE-A1 transfected 293 cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

MAGE-A1 (h): 293 Lysate is suitable as a Western Blotting positive control for human reactive MAGE-A1 antibodies. Recommended use: 10-20 μ l ner lane


Control 293 Lysate: sc-110760 is available as a Western Blotting negative control lysate derived from non-transfected 293 cells.


MAGE-A1 (MA454): sc-20033 is recommended as a positive control antibody for Western Blot analysis of enhanced human MAGE-A1 expression in MAGE-A1 transfected 293 cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA







MAGE-A1 (3F256): sc-71539. Western blot analysis of MAGE-A1 expression in non-transfected: sc-110760 (**A**) and human MAGE-A1 transfected: sc-112260 (**B**) 293 whole cell levetse

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com